Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CAD106

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Alzheimer's disease (AD) pathology, including the accumulation of amyloid beta (Aβ) species and tau pathology, begins decades… Expand
Review
2017
Review
2017
Amyloid beta peptide (Aβ) is produced through the proteolytic processing of a transmembrane protein, amyloid precursor protein… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
2017
2017
This randomized, double‐blind, placebo‐controlled, 90‐week study assessed safety, tolerability, and immunogenicity of CAD106 with… Expand
Highly Cited
2015
Highly Cited
2015
IntroductionCAD106 is designed to stimulate amyloid-β (Aβ)-specific antibody responses while avoiding T-cell autoimmune responses… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Review
2014
Review
2014
Both active and passive anti-β-amyloid (Aβ) immunotherapies for the treatment of Alzheimer's disease (AD) have demonstrated… Expand
Review
2014
Review
2014
Dementia is a public health priority and one of the major contributors to morbidity and global non-communicable disease burden… Expand
Highly Cited
2012
Highly Cited
2012
BACKGROUND Immunotherapy targeting the amyloid β (Aβ) peptide is a potential strategy to slow the progression of Alzheimer's… Expand
2012
2012
Alzheimer disease: Amyloid-β immunotherapy CAD106 passes first safety test in patients with Alzheimer disease 
2012
2012
Alzheimer’s disease is the most common cause of dementia globally, affecting about 36 million people at present and with about… Expand
Highly Cited
2011
Highly Cited
2011
Immunization against amyloid-β (Aβ) can reduce amyloid accumulation in vivo and is considered a potential therapeutic approach… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3